Integrating F-FDG PET/CT with Lung Dose-volume for Assessing Lung Inflammatory Changes After Arc-based Radiotherapy for Esophageal Cancer: A Pilot Study

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2022 Sep 27

PMID 36163634

Authors

Chen-Xiong Hsu

Kuan-Heng Lin

Pei-Wei Shueng

Yen-Wen Wu

Wei-Ta Tsai

Chiu-Han Chang

Hui-Ju Tien

Shan-Ying Wang

Tung-Hsin Wu

Greta S P Mok

Affiliations

Soon will be listed here.

Abstract

Objective: The incidence of radiation pneumonitis (RP) has a highly linear relationship with low-dose lung volume. We previously established a volume-based algorithm (VBA) method to improve low-dose lung volume in radiotherapy (RT). This study assessed lung inflammatory changes by integrating fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ( F-FDG PET/CT) with VBA for esophageal cancer patients undergoing arc-based RT.

Methods: Thirty esophageal cancer patients received F-FDG PET/CT imaging pre-RT and post-RT were included in a retrospective pilot study. We fused lung doses and parameters of PET/CT in RT planning. Based on VBA, we used the 5Gy isodose curve to define high-dose (HD) and low-dose (LD) regions in the lung volume. We divided patients into non-RP (nRP) and RP groups. The maximum, mean standardized uptake value (SUVmax, SUVmean), global lung glycolysis (GLG), mean lung dose (MLD) and V in lungs were analyzed. Area under the curve values were utilized to identify optimal cut-off values for RP.

Results: Eleven patients in the nRP group and 19 patients in the RP group were identified. In 30 RP lungs, post-RT SUVmax, SUVmean and GLG of HD regions showed significant increases compared to values for pre-RT lungs. There were no significant differences in values of 22 nRP lungs. Post-RT SUVmax and SUVmean of HD regions, MLD, and lung V and V in RP lungs were significantly higher than in nRP lungs. For detecting RP, the optimal cut-off values were post-RT SUVmax > 2.28 and lung V > 47.14%.

Conclusion: This study successfully integrated F-FDG PET/CT with VBA to assess RP in esophageal cancer patients undergoing RT. Post-RT SUVmax > 2.28 and lung V > 47.14% might be potential indicators of RP.

Citing Articles

Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.

Shueng P, Huang C, Liu Y, Wu Y, Huang P, Yen S Thorac Cancer. 2022; 14(2):143-148.

PMID: 36351568 PMC: 9834687. DOI: 10.1111/1759-7714.14724.

Comments on "dynamic F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer".

Wang S, Shiau Y, Hsu C Thorac Cancer. 2022; 13(24):3513-3514.

PMID: 36288468 PMC: 9750810. DOI: 10.1111/1759-7714.14710.

Integrating F-FDG PET/CT with lung dose-volume for assessing lung inflammatory changes after arc-based radiotherapy for esophageal cancer: A pilot study.

Hsu C, Lin K, Shueng P, Wu Y, Tsai W, Chang C Thorac Cancer. 2022; 13(22):3114-3123.

PMID: 36163634 PMC: 9663684. DOI: 10.1111/1759-7714.14661.

References

Jo I, Kay C, Kim J, Son S, Kang Y, Jung J . Significance of low-dose radiation distribution in development of radiation pneumonitis after helical-tomotherapy-based hypofractionated radiotherapy for pulmonary metastases. J Radiat Res. 2013; 55(1):105-12. PMC: 3885113. DOI: 10.1093/jrr/rrt080. View

GRAHAM M, Purdy J, Emami B, Harms W, Bosch W, Lockett M . Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999; 45(2):323-9. DOI: 10.1016/s0360-3016(99)00183-2. View

Jain V, Berman A . Radiation Pneumonitis: Old Problem, New Tricks. Cancers (Basel). 2018; 10(7). PMC: 6071030. DOI: 10.3390/cancers10070222. View

Libshitz H, SOUTHARD M . Complications of radiation therapy: the thorax. Semin Roentgenol. 1974; 9(1):41-9. DOI: 10.1016/0037-198x(74)90008-x. View

Jahangiri P, Pournazari K, Torigian D, Werner T, Swisher-McClure S, Simone 2nd C . A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy. Eur J Nucl Med Mol Imaging. 2018; 46(1):206-216. DOI: 10.1007/s00259-018-4154-5. View

Zhang Y, Yu Y, Yu J, Fu Z, Liu T, Guo S . FDG PET-CT standardized uptake value for the prediction of radiation pneumonitis in patients with lung cancer receiving radiotherapy. Oncol Lett. 2016; 10(5):2909-2914. PMC: 4665373. DOI: 10.3892/ol.2015.3637. View

Ben-Haim S, Ell P . 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med. 2009; 50(1):88-99. DOI: 10.2967/jnumed.108.054205. View

Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

Stumpe K, Dazzi H, Schaffner A, von Schulthess G . Infection imaging using whole-body FDG-PET. Eur J Nucl Med. 2000; 27(7):822-32. DOI: 10.1007/s002590000277. View

10.

Wang S, Liao Z, Wei X, Liu H, Tucker S, Hu C . Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006; 66(5):1399-407. DOI: 10.1016/j.ijrobp.2006.07.1337. View

11.

Abdulla S, Salavati A, Saboury B, Basu S, Torigian D, Alavi A . Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study. Eur J Nucl Med Mol Imaging. 2013; 41(2):350-6. DOI: 10.1007/s00259-013-2579-4. View

12.

Hsu C, Lin K, Shueng P, Wu Y, Tsai W, Chang C . Integrating F-FDG PET/CT with lung dose-volume for assessing lung inflammatory changes after arc-based radiotherapy for esophageal cancer: A pilot study. Thorac Cancer. 2022; 13(22):3114-3123. PMC: 9663684. DOI: 10.1111/1759-7714.14661. View

13.

Petit S, van Elmpt W, Oberije C, Vegt E, Dingemans A, Lambin P . [¹⁸F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients. Int J Radiat Oncol Biol Phys. 2010; 81(3):698-705. DOI: 10.1016/j.ijrobp.2010.06.016. View

14.

De Ruysscher D, Houben A, Aerts H, Dehing C, Wanders R, Ollers M . Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study. Radiother Oncol. 2009; 91(3):415-20. DOI: 10.1016/j.radonc.2009.01.004. View

15.

Tanabe S, Myojin M, Shimizu S, Fujino M, Takahashi H, Shirato H . Dose-volume analysis for respiratory toxicity in intrathoracic esophageal cancer patients treated with definitive chemoradiotherapy using extended fields. J Radiat Res. 2013; 54(6):1085-94. PMC: 3823774. DOI: 10.1093/jrr/rrt047. View

16.

Hong J, Kim H, Han E, Byun J, Jang H, Choi E . Total Lesion Glycolysis Using ¹⁸F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer. J Korean Med Sci. 2016; 31(1):39-46. PMC: 4712578. DOI: 10.3346/jkms.2016.31.1.39. View

17.

Mok G, Choi F, Chu W . Actinomycosis imitating parotid cancer with metastatic lymph nodes in FDG PET/CT. Clin Nucl Med. 2011; 36(4):309-10. DOI: 10.1097/RLU.0b013e31820a9fbf. View

18.

Guerrero T, Johnson V, Hart J, Pan T, Khan M, Luo D . Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol Biol Phys. 2007; 68(4):1030-5. DOI: 10.1016/j.ijrobp.2007.01.031. View

19.

Ajani J, DAmico T, Almhanna K, Bentrem D, Besh S, Chao J . Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015; 13(2):194-227. DOI: 10.6004/jnccn.2015.0028. View

20.

Rice T, Blackstone E, Rusch V . 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010; 17(7):1721-4. DOI: 10.1245/s10434-010-1024-1. View